Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 642

1.

Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT.

Baron F, Labopin M, Savani BN, Beohou E, Niederwieser D, Eder M, Potter V, Kröger N, Beelen D, Socié G, Itälä-Remes M, Bornhäuser M, Mohty M, Nagler A.

Br J Haematol. 2019 Oct 14. doi: 10.1111/bjh.16185. [Epub ahead of print]

PMID:
31612473
2.

Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group.

Mohty M, Malard F, Abecasis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Basak G, Bazarbachi A, Blaise D, Ciceri F, Corbacioglu S, Dalle JH, Dignan F, Fukuda T, Huynh A, Kuball J, Lachance S, Lazarus H, Masszi T, Michallet M, Nagler A, NiChonghaile M, Okamoto S, Pagliuca A, Peters C, Petersen FB, Richardson PG, Ruutu T, Saber W, Savani BN, Soiffer R, Styczynski J, Wallhult E, Yakoub-Agha I, Duarte RF, Carreras E.

Bone Marrow Transplant. 2019 Oct 1. doi: 10.1038/s41409-019-0705-z. [Epub ahead of print] No abstract available.

PMID:
31576023
3.

Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party.

Bazarbachi AH, Al Hamed R, Labopin M, Afanasyev B, Hamladji RM, Beelen D, Eder M, Scheid C, Wu D, Bunjes D, Stepensky P, Tischer J, Kröger N, Peric Z, Aljurf M, Giebel S, Nagler A, Mohty M.

Bone Marrow Transplant. 2019 Sep 27. doi: 10.1038/s41409-019-0702-2. [Epub ahead of print]

PMID:
31562398
4.

Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes.

Stocker N, Labopin M, Boussen I, Paccoud O, Bonnin A, Malard F, Amiel C, Gozlan J, Battipaglia G, Duléry R, Giannotti F, Ruggeri A, Gaugler B, Mohty M, Brissot E.

Bone Marrow Transplant. 2019 Sep 27. doi: 10.1038/s41409-019-0699-6. [Epub ahead of print]

PMID:
31562397
5.

A novel mouse model of acute graft-versus-host disease based on chemotherapy conditioning and G-CSF mobilized graft.

Ye Y, Ricard L, Stocker N, Mohty M, Gaugler B, Malard F.

Bone Marrow Transplant. 2019 Sep 26. doi: 10.1038/s41409-019-0700-4. [Epub ahead of print]

PMID:
31558787
6.

Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia.

Debureaux PE, Labopin M, Mamez AC, Lapusan S, Isnard F, Adaeva R, Bonnin A, Hirsch P, Delhommeau F, Battipaglia G, Duléry R, Malard F, Vekhoff A, Mohty M, Legrand O, Brissot E.

Bone Marrow Transplant. 2019 Sep 25. doi: 10.1038/s41409-019-0690-2. [Epub ahead of print]

PMID:
31554931
7.

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT.

Dholaria B, Savani BN, Labopin M, Luznik L, Ruggeri A, Mielke S, Al Malki MM, Kongtim P, Fuchs E, Huang XJ, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Ben Soussan P, Arnault Y, Handgretinger R, Roy DC, O'Donnell P, Bashey A, Solomon S, Romee R, Lewalle P, Gayoso J, Maschan M, Lazarus HM, Ballen K, Giebel S, Baron F, Ciceri F, Esteve J, Gorin NC, Spyridonidis A, Schmid C, Ciurea SO, Nagler A, Mohty M.

Haematologica. 2019 Sep 19. pii: haematol.2019.219790. doi: 10.3324/haematol.2019.219790. [Epub ahead of print]

8.

Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study.

Gatwood KS, Labopin M, Savani BN, Finke J, Socie G, Beelen D, Yakoub-Agha I, Chevallier P, Ganser A, Blaise D, Milpied N, Bruno L, Mailhol A, Mohty M, Nagler A.

Bone Marrow Transplant. 2019 Sep 16. doi: 10.1038/s41409-019-0673-3. [Epub ahead of print]

PMID:
31527819
9.

Gut microbiota alteration during allogeneic haematopoietic cell transplantation: what can we do?

Malard F, Mohty M.

Br J Haematol. 2019 Sep 16. doi: 10.1111/bjh.16204. [Epub ahead of print] No abstract available.

PMID:
31524291
10.

Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study.

Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, Diez-Martin JL, Tischer J, Gülbas Z, Wallet HL, Corral LL, Mohty M, Koc Y, Yakoub-Agha I, Schmid C, El Cheikh J, Arat M, Forcade E, Dreger P, Rocha V, García GG, Chalandon Y, Ferra C, Orvain C, Robinson S, Montoto S, Sureda A.

Br J Haematol. 2019 Sep 9. doi: 10.1111/bjh.16182. [Epub ahead of print]

PMID:
31498883
11.

Infectious complications after post-transplantation cyclophosphamide and anti-thymocyte globulin-based haploidentical stem cell transplantation.

Mohty R, Brissot E, Battipaglia G, Ruggeri A, Dulery R, Bonnin A, Médiavilla C, Sestili S, Belhocine R, Vekhoff A, Ledraa T, Lapusan CS, Adaeva R, Isnard F, Legrand O, Mohty M, Malard F.

Br J Haematol. 2019 Sep 5. doi: 10.1111/bjh.16189. [Epub ahead of print] No abstract available.

PMID:
31487392
12.

Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.

Shouval R, Fein JA, Labopin M, Kröger N, Duarte RF, Bader P, Chabannon C, Kuball J, Basak GW, Dufour C, Galimard JE, Polge E, Lankester A, Montoto S, Snowden JA, Styczynski J, Yakoub-Agha I, Mohty M, Nagler A.

Lancet Haematol. 2019 Aug 30. pii: S2352-3026(19)30158-9. doi: 10.1016/S2352-3026(19)30158-9. [Epub ahead of print]

PMID:
31477550
13.

Exploring the microvascular impact of red blood cell transfusion in intensive care unit patients.

Hariri G, Bourcier S, Marjanovic Z, Joffre J, Lemarié J, Lavillegrand JR, Charue D, Duflot T, Bigé N, Baudel JL, Maury E, Mohty M, Guidet B, Bellien J, Blanc-Brude O, Ait-Oufella H.

Crit Care. 2019 Aug 30;23(1):292. doi: 10.1186/s13054-019-2572-9.

14.

Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors.

Styczyński J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, Mikulska M, Gil L, Cordonnier C, Ljungman P, Averbuch D, Cesaro S, de la Camara R, Baldomero H, Bader P, Basak G, Bonini C, Duarte R, Dufour C, Kuball J, Lankester A, Montoto S, Nagler A, Snowden JA, Kröger N, Mohty M, Gratwohl A; Infectious Diseases Working Party EBMT.

Bone Marrow Transplant. 2019 Aug 27. doi: 10.1038/s41409-019-0624-z. [Epub ahead of print]

PMID:
31455899
15.

Relapsed refractory multiple myeloma: a comprehensive overview.

Bazarbachi AH, Al Hamed R, Malard F, Harousseau JL, Mohty M.

Leukemia. 2019 Oct;33(10):2343-2357. doi: 10.1038/s41375-019-0561-2. Epub 2019 Aug 27. Review.

PMID:
31455853
16.

Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations.

Aljurf M, Weisdorf D, Hashmi SK, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Ali Hamidieh A, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas M, Ahmed SO, Novitsky N, Srivastava A, Seber A, Elsolh H, Ghavamzadeh A, Confer D, Kodera Y, Greinix H, Szer J, Horowitz M, Niederwieser D.

Hematol Oncol Stem Cell Ther. 2019 Aug 20. pii: S1658-3876(19)30055-X. doi: 10.1016/j.hemonc.2019.08.002. [Epub ahead of print]

17.

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y.

Biol Blood Marrow Transplant. 2019 Aug 22. pii: S1083-8791(19)30529-4. doi: 10.1016/j.bbmt.2019.08.015. [Epub ahead of print] Review.

PMID:
31446199
18.

Hematopoietic Cell Transplant Consideration for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia Patients.

El Fakih R, Savani B, Mohty M, Aljurf M.

Biol Blood Marrow Transplant. 2019 Aug 21. pii: S1083-8791(19)30524-5. doi: 10.1016/j.bbmt.2019.08.010. [Epub ahead of print] Review.

PMID:
31445182
19.

Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Halaburda K, Labopin M, Mailhol A, Socié G, Craddock C, Aljurf M, Beelen D, Cornelissen JJ, Bourhis JH, Labussière-Wallet H, Blaise D, Gedde-Dahl T, Gilleece M, Yakoub-Agha I, Mufti G, Esteve J, Mohty M, Nagler A.

Haematologica. 2019 Aug 22. pii: haematol.2019.222810. doi: 10.3324/haematol.2019.222810. [Epub ahead of print]

20.

Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?

Shichijo T, Fuji S, Nagler A, Bazarbachi A, Mohty M, Savani BN.

Bone Marrow Transplant. 2019 Aug 21. doi: 10.1038/s41409-019-0643-9. [Epub ahead of print] Review.

PMID:
31435032
21.

Features of Toxoplasma gondii reactivation after allogeneic hematopoietic stem-cell transplantation in a high seroprevalence setting.

Paccoud O, Guitard J, Labopin M, Surgers L, Malard F, Battipaglia G, Duléry R, Hennequin C, Mohty M, Brissot E.

Bone Marrow Transplant. 2019 Aug 21. doi: 10.1038/s41409-019-0641-y. [Epub ahead of print]

PMID:
31435031
22.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S.

N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455.

PMID:
31433920
23.

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.

Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J.

Leukemia. 2019 Aug 19. doi: 10.1038/s41375-019-0539-0. [Epub ahead of print]

PMID:
31427722
24.

Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT.

Shem-Tov N, Peczynski C, Labopin M, Itälä-Remes M, Blaise D, Labussière-Wallet H, Socié G, Kröger N, Mielke S, Afanasyev B, Chevallier P, Tischer J, Helbig G, Jindra P, Peric Z, Giebel S, Mohty M, Nagler A.

Leukemia. 2019 Aug 19. doi: 10.1038/s41375-019-0544-3. [Epub ahead of print]

PMID:
31427719
25.

Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin.

Baron F, Galimard JE, Labopin M, Yakoub-Agha I, Niittyvuopio R, Kröger N, Griskevicius L, Wu D, Forcade E, Richard C, Aljurf M, Helbig G, Labussière-Wallet H, Mohty M, Nagler A.

Haematologica. 2019 Aug 14. pii: haematol.2019.227603. doi: 10.3324/haematol.2019.227603. [Epub ahead of print]

26.

Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study.

Kanda J, Hayashi H, Ruggeri A, Kimura F, Volt F, Takahashi S, Labopin M, Kako S, Tozatto-Maio K, Yano S, Sanz G, Uchida N, Van Lint MT, Kato S, Mohty M, Forcade E, Kanamori H, Sierra J, Ohno Y, Saccardi R, Fukuda T, Ichinohe T, Takanashi M, Rocha V, Okamoto S, Nagler A, Atsuta Y, Gluckman E.

Leukemia. 2019 Aug 14. doi: 10.1038/s41375-019-0534-5. [Epub ahead of print]

PMID:
31409921
27.

Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Giebel S, Boumendil A, Labopin M, Seesaghur A, Baron F, Ciceri F, Esteve J, Gorin NC, Savani B, Schmid C, Wetten S, Mohty M, Nagler A.

Ann Hematol. 2019 Oct;98(10):2389-2398. doi: 10.1007/s00277-019-03771-2. Epub 2019 Aug 7.

28.

Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.

Gilleece MH, Labopin M, Savani BN, Yakoub-Agha I, Socié G, Gedde-Dahl T, Blaise D, Byrne JL, Craddock C, Cornelissen JJ, Arcese W, Forcade E, Crawley C, Polge E, Mohty M, Nagler A.

Leukemia. 2019 Jul 30. doi: 10.1038/s41375-019-0527-4. [Epub ahead of print]

PMID:
31363160
29.

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.

Landgren O, Sonneveld P, Jakubowiak A, Mohty M, Iskander KS, Mezzi K, Siegel DS.

Leukemia. 2019 Sep;33(9):2127-2143. doi: 10.1038/s41375-019-0517-6. Epub 2019 Jul 24. Review.

30.

Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.

Jaimes-Albornoz D, Mannone L, Nguyen-Quoc S, Chalandon Y, Chevallier P, Mohty M, Meunier M, Robin M, Ledoux MP, Guillerm G, Bay JO, Poiré X, Maillard N, Leclerc M, Daguindau E, Beguin Y, Rubio MT, Gyan E.

Biol Blood Marrow Transplant. 2019 Jul 19. pii: S1083-8791(19)30445-8. doi: 10.1016/j.bbmt.2019.07.013. [Epub ahead of print]

PMID:
31326611
31.

Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT.

Piemontese S, Boumendil A, Labopin M, Schmid C, Ciceri F, Arcese W, Koc Y, Gulbas Z, Tischer J, Bruno B, Wu D, Blaise D, Beelen D, Irrera G, Ruggeri A, Houhou M, Mohty M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

J Hematol Oncol. 2019 Jul 4;12(1):68. doi: 10.1186/s13045-019-0751-4.

32.

Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Shimoni A, Labopin M, Savani B, Byrne M, Volin L, Finke J, Niederwieser D, Ehninger G, Blaise D, Beelen D, Tabrizi R, Sengeloev H, Ganser A, Cornelissen JJ, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2019 Jul 2. pii: S1083-8791(19)30415-X. doi: 10.1016/j.bbmt.2019.06.031. [Epub ahead of print]

PMID:
31271887
33.

Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation.

Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, Schetelig J, Ganser A, Blaise D, Itälä-Remes M, Passweg JR, Bonifazi F, Finke J, Ruggeri A, Nagler A, Mohty M.

Blood. 2019 Sep 12;134(11):892-899. doi: 10.1182/blood.2019000487. Epub 2019 Jul 3.

PMID:
31270102
34.

Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.

Nagler A, Labopin M, Dholaria B, Niittyvuopio R, Maertens J, Poiré X, Cornelissen J, Reményi P, Bourhis JH, Beguin Y, Malladi R, Kerre T, Schroyens W, Savani BN, Mohty M.

Blood Adv. 2019 Jul 9;3(13):1950-1960. doi: 10.1182/bloodadvances.2019000030.

35.

Nuke less for less cancer.

Mohty M.

Blood. 2019 Jun 27;133(26):2738-2739. doi: 10.1182/blood.2019001176. No abstract available.

PMID:
31248875
36.

Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia.

Shouval R, Labopin M, Gorin NC, Bomze D, Houhou M, Blaise D, Zuckerman T, Baerlocher GM, Capria S, Forcade E, Huynh A, Saccardi R, Martino M, Schaap M, Wu D, Mohty M, Nagler A.

Cancer. 2019 Oct 15;125(20):3566-3573. doi: 10.1002/cncr.32344. Epub 2019 Jun 21.

PMID:
31225904
37.

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial.

Boyle EM, Leleu X, Petillon MO, Karlin L, Doyen C, Demarquette H, Royer B, Macro M, Moreau P, Fostier K, Marie-Lorraine C, Zarnitsky C, Perrot A, Herbaux C, Poulain S, Manier S, Beauvais D, Walker BA, Wardell CP, Vincent L, Frenzel L, Caillon H, Susanna S, Dejoie T, Avet-Loiseau H, Mohty M, Facon T; IFM2014-04 investigators.

Br J Haematol. 2019 Jun 19. doi: 10.1111/bjh.16059. [Epub ahead of print]

PMID:
31218679
38.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Ringdén O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, Niederwieser D, Finke J, Stelljes M, Gerbitz A, Ganser A, Kröger N, Kantz L, Brecht A, Savani B, Sadeghi B, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2019 Oct;25(10):1975-1983. doi: 10.1016/j.bbmt.2019.05.037. Epub 2019 Jun 7.

PMID:
31181255
39.

Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT.

Ruutu T, van der Werf S, van Biezen A, Backman JT, Peczynski C, Kröger N, Mohty M, Nagler A, Montoto S, Langebrake C, Niederwieser D, Peric Z, Koenecke C, Duarte RF, Basak G.

Bone Marrow Transplant. 2019 Jun 3. doi: 10.1038/s41409-019-0579-0. [Epub ahead of print]

PMID:
31160806
40.

Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT.

Ruggeri A, Labopin M, Savani B, Paviglianiti A, Blaise D, Volt F, Ciceri F, Bacigalupo A, Tischer J, Chevallier P, Koc Y, Cornelissen JJ, Ehninger G, Sanz G, Deconinck E, Rocha V, Baron F, Mohty M, Gluckman E, Nagler A.

Bone Marrow Transplant. 2019 May 31. doi: 10.1038/s41409-019-0582-5. [Epub ahead of print]

PMID:
31150016
41.

Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement.

McCune JS, Quinones CM, Ritchie J, Carpenter PA, van Maarseveen E, Yeh RF, Anasetti C, Boelens JJ, Hamerschlak N, Hassan M, Kang HJ, Kanda Y, Paci A, Perales MA, Shaw PJ, Seewaldt VL, Savani BN, Hsieh A, Poon B, Mohty M, Pulsipher MA, Pasquini M, Dupuis LL.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1890-1897. doi: 10.1016/j.bbmt.2019.05.021. Epub 2019 May 25.

PMID:
31136799
42.

Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Graft Failure Patients: a Report on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.

Prata PH, Resche-Rigon M, Blaise D, Socié G, Rohrlich PS, Milpied N, Turlure P, Nguyen S, Sirvent A, Bulabois CE, Berceanu A, Charbonnier A, Chevallier P, Bay JO, Neven B, Jubert C, Mohty M, Rubio MT, Peffault de Latour R.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1798-1802. doi: 10.1016/j.bbmt.2019.05.013. Epub 2019 May 24.

PMID:
31129355
43.

Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.

Battipaglia G, Massoud R, Ahmed SO, Legrand O, El Cheikh J, Youniss R, Aljurf M, Mohty M, Bazarbachi A.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):506-508. doi: 10.1016/j.clml.2019.04.004. Epub 2019 Apr 18.

PMID:
31122828
44.

Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation.

Nagler A, Labopin M, Dholaria B, Finke J, Brecht A, Schanz U, Niittyvuopio R, Neubauer A, Bornhäuser M, Santarone S, Beelen D, Shimoni A, Rösler W, Giebel S, Savani BN, Mohty M.

Br J Haematol. 2019 Sep;186(5):767-776. doi: 10.1111/bjh.15973. Epub 2019 May 22.

PMID:
31115916
45.

Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.

Mohty M, Cavo M, Fink L, Gonzalez-McQuire S, Leleu H, Mateos MV, Raab MS, Schoen P, Yong K.

Eur J Haematol. 2019 Aug;103(2):107-115. doi: 10.1111/ejh.13264. Epub 2019 Jun 18.

PMID:
31112311
46.

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Bone Marrow Transplant. 2019 May 15. doi: 10.1038/s41409-019-0451-2. [Epub ahead of print]

PMID:
31092900
47.

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.

Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien ML, Royer B, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Fontan J, Voillat L, Demarquette H, Collet P, Rodon P, Sohn C, Lifermann F, Orsini-Piocelle F, Richez V, Mohty M, Macro M, Minvielle S, Moreau P, Leleu X, Facon T, Attal M, Avet-Loiseau H, Corre J.

J Clin Oncol. 2019 Jul 1;37(19):1657-1665. doi: 10.1200/JCO.18.00776. Epub 2019 May 15.

PMID:
31091136
48.
49.

Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.

Guillaume T, Malard F, Magro L, Labopin M, Tabrizi R, Borel C, Chevallier P, Vigouroux S, Peterlin P, Garnier A, Rubio MT, Huynh A, Milpied N, Moreau P, Gaugler B, Yakoub-Agha I, Mohty M.

Bone Marrow Transplant. 2019 May 14. doi: 10.1038/s41409-019-0536-y. [Epub ahead of print]

PMID:
31089280
50.

Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT.

Poiré X, Labopin M, Polge E, Forcade E, Ganser A, Volin L, Michallet M, Blaise D, Yakoub-Agha I, Maertens J, Richard Espiga C, Cornelissen J, Finke J, Mohty M, Esteve J, Nagler A; Acute Leukemia Working Party of the EBMT.

Haematologica. 2019 May 2. pii: haematol.2019.216168. doi: 10.3324/haematol.2019.216168. [Epub ahead of print]

Supplemental Content

Support Center